心力衰竭预防:证据生成、试验设计与监管路径
本文综述心力衰竭预防的现状与挑战。美国约三分之二成人处于A期或B期前临床阶段,但尚无药物获批用于HF一级预防。作者提出需从以冠心病为基础的方法逐步转向更广泛人群,重新评估预防策略、事件定义与监管路径。
要点
- 心力衰竭终生风险为1/4,约三分之二美国成人处于A期或B期前临床阶段。
- 目前尚无治疗药物获批专门用于心力衰竭的一级预防。
- 传统以住院为基础的HF事件定义忽略了多数在门诊确诊的病例。
核心结论
- 心力衰竭预防需要从根本上重新评估,逐步从冠心病为基础的策略转向更广泛人群。
- 心衰事件定义、试验时长和监管路径均面临实践挑战,需建立新的证据生成框架。
研究设计与样本
- 本文为综述,回顾现有心衰预防相关证据、当前及进行中的预防试验,并讨论试验设计与监管路径。
主要发现
- 心力衰竭终生发病风险为1/4,美国约三分之二成人处于A期或B期前临床阶段。
- 动脉粥样硬化性心血管疾病已有明确预防指南和获批药物,而心衰预防尚不成熟。
- 多数试验仅报告首次心衰住院,而门诊是大多数心衰确诊的场景。
- 许多心衰病例源于非动脉粥样硬化性病因,如肥胖、高血压、癌症治疗和心肾代谢综合征。
临床怎么用
- 应关注A期和B期前临床人群,识别肥胖、高血压、癌症治疗及心肾代谢综合征等非动脉粥样硬化性心衰风险因素。
- 评估心衰预防效果时需纳入门诊诊断的事件,不能仅依赖住院定义。
局限性
- 心力衰竭预防尚无获批药物,现有试验证据有限。
- 传统住院为基础的HF事件定义不能覆盖门诊确诊的心衰病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure (HF) is a public health challenge with high morbidity and mortality risk, and societal economic costs. The lifetime risk of developing HF stands at 1 in 4. A significant portion of the population already is in precursor stages, with roughly two-thirds of adults in the United States classified as either stage A (at risk) or stage B (pre-HF). Despite advances in drugs and device-based therapies, once HF develops, these patients remain at an unacceptably high risk for mortality, morbidity, and adverse health status, underscoring the need for focus on primary prevention of HF. The prevention of atherosclerotic cardiovascular disease is supported by established guidelines with clear targets and pharmacotherapies with specific labels for prevention. However, prevention of HF remains less well established. No therapeutic agent is approved yet specifically for the primary prevention of HF. Defining and adjudicating incident HF is challenging. Most trials report initial HF hospitalizations only. The conventional hospitalization-based definition of incident HF does not take into account outpatient settings where most HF is diagnosed. A fundamental reevaluation of preventive strategies for HF is required, moving incrementally from coronary disease-based approaches to more global populations, because many HF cases arise from nonatherosclerotic causes, such as obesity, hypertension, cancer therapies, and the cardio-kidney-metabolic syndrome. This review addresses practical challenges in defining incident HF, trial duration, and regulatory pathways, while summarizing the landscape of current and ongoing prevention trials, identifying evidence gaps, and highlighting future priorities.
引用
- Butler, Khan, Ferreira, et al. Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways. J Am Coll Cardiol. 2026. PMID: 41670570. doi:10.1016/j.jacc.2025.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。